Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00823901 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
NCT00823901: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT00823901 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 83 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00823901, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel are effective and safe in the treatment of papulopustular rosacea.
Interventions
- DRUG Placebo gel
- DRUG Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2009-02 |
| Est. Completion | 2010-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00823901
The ClinicalTrials.gov registry entry for NCT00823901 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo gel is the first listed.
NCT00823901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00823901 about?
NCT00823901 is a clinical study titled "Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea". The purpose of this study is to determine whether Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel are effective and safe in the treatment of papulopustular rosacea.
What is the current status of trial NCT00823901?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2009-02. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00823901?
The interventions under investigation include: Placebo gel (DRUG), Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel (DRUG).
Who is sponsoring clinical trial NCT00823901?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.